New cocktail hopes to tame tough pancreatic cancer
NCT ID NCT05026905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shrinking tumors and delaying progression. About 66 participants are enrolled across multiple centers in Taiwan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, nab-paclitaxel, S-1, leucovorin, oxaliplatin
What this could lead to
If successful, this could point toward a more effective first-line treatment for metastatic pancreatic cancer, potentially extending the time patients live without the disease worsening.
What could go wrong
This is a small, early-phase trial (66 participants) testing two experimental combinations. The results may not lead to a new standard of care, and the added drugs could increase side effects without improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 400, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 800, Taiwan
-
National Cheng Kung University Hospital
Tainan, 600, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan